<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29805504</article-id><article-id pub-id-type="pmc">5952089</article-id><article-id pub-id-type="doi">10.3892/etm.2018.5995</article-id><article-id pub-id-type="publisher-id">ETM-0-0-5995</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Curative effects of GM1 in the treatment of severe ischemic brain injury and its effects on serum TNF-&#x003b1; and NDS</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fang</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5995">1</xref><xref rid="fn1-etm-0-0-5995" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiaoling</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5995">1</xref><xref rid="fn1-etm-0-0-5995" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yunxia</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5995">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Guoliang</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-5995">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yancang</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-5995">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yiwu</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-5995">2</xref><xref rid="c1-etm-0-0-5995" ref-type="corresp"/></contrib></contrib-group><aff id="af1-etm-0-0-5995"><label>1</label>Department of Neurosurgery Medicine, Yantai Yuhuangding Hospital of Shandong, Yantai, Shandong 264000, P.R. China</aff><aff id="af2-etm-0-0-5995"><label>2</label>Department of Emergency Medicine, The First People's Hospital of Jining, Jining, Shandong 272011, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-5995"><italic>Correspondence to</italic>: Dr Yiwu Zhang, Department of Emergency Medicine, The First People's Hospital of Jining, 6 Jiankang Road, Jining, Shandong 272011, P.R. China, E-mail: <email>zhangyiwusd@126.com</email></corresp><fn id="fn1-etm-0-0-5995"><label>*</label><p>Contributed equally</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>3</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>15</volume><issue>6</issue><fpage>4851</fpage><lpage>4855</lpage><history><date date-type="received"><day>21</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Liu et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The curative effects of monosialotetrahexosyl ganglioside (GM1) in the treatment of severe ischemic brain injury and its effects on tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and neuropathy disability score (NDS). Sixty patients with severe ischemic brain injury admitted to The First People's Hospital of Jining (Jining, China) from June 2014 to March 2016 were selected. They were randomly divided into the control group (n=30) and the experimental group (n=30). The patients in the control group were treated with routine therapy while those in the experimental group were treated with GM1. The level of TNF-&#x003b1; in the serum was measured by the enzyme-linked immunosorbent assay. The NDS was used to grade the two groups; Pearson's correlation coefficient was applied to analyze the correlation between the content of TNF-&#x003b1; and NDS; the content of superoxide dismutase (SOD) was detected using xanthine oxidase assay, and the content of malondialdehyde (MDA) was detected by thiobarbituric acid method. The clinical recovery time of two groups of patients was recorded. At 14 days after GM1 treatment, the serum TNF-&#x003b1; content and the NDS in the experimental group were significantly lower than those in the control group (P&#x0003c;0.05). The content of TNF-&#x003b1; in the patients was positively correlated with the NDS. After treatment, the serum MDA content of patients in the experimental group was lower, while the SOD content was significantly higher than that in the control group (P&#x0003c;0.05). After GM1 treatment, hemodynamic parameters of patients in the experimental group were significantly improved compared with those in the control group. The total effective rate of GM1 treatment in the experimental group was higher than that in the control group (P&#x0003c;0.05). GM1 has a good clinical significance in the treatment of patients with severe ischemic brain injury and is worthy of clinical promotion and application.</p></abstract><kwd-group><kwd>monosialotetrahexosyl ganglioside</kwd><kwd>tumor necrosis factor-&#x003b1;</kwd><kwd>neuropathy disability score</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Severe ischemic brain damage belongs to a disease type of cerebral infarction and is a global health problem (<xref rid="b1-etm-0-0-5995" ref-type="bibr">1</xref>). According to statistics, patients with this disease often suffer limb paralysis, fall into a coma or even die. Its mortality rate is 20&#x02013;35%, and the morbidity rate and recurrence rate are also very high (<xref rid="b2-etm-0-0-5995" ref-type="bibr">2</xref>,<xref rid="b3-etm-0-0-5995" ref-type="bibr">3</xref>). At present, the main drugs for the treatment of ischemic brain injury are glutamate receptor antagonists, calcium channel blockers, free radical scavengers, anti-inflammatory and anti-apoptotic drugs (<xref rid="b4-etm-0-0-5995" ref-type="bibr">4</xref>,<xref rid="b5-etm-0-0-5995" ref-type="bibr">5</xref>). Although the relevant study has made significant progress in many key mechanisms and processes of injury, clinical trials of neurological protection in patients with ischemic brain injury bring little effect (<xref rid="b6-etm-0-0-5995" ref-type="bibr">6</xref>). Over the past few years, it was found that the neuroprotective drug monosialotetrahexosyl ganglioside (GM1) promotes growth and repair the neurological impairment. As reported, the exogenous GM1 has been used to promote the nervous system cell regeneration and synapse formation (<xref rid="b7-etm-0-0-5995" ref-type="bibr">7</xref>,<xref rid="b8-etm-0-0-5995" ref-type="bibr">8</xref>). However, the role of GM1 in patients with severe ischemic brain injury is rarely reported. This study focused on the systematic evaluation of the curative effect of GM1 in the treatment of patients with severe ischemic brain injury.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Data of patients</title><p>A total of 60 patients with severe ischemic brain injury who were admitted to the Department of Emergency Medicine of Jining Hospital (Jining, China) from June 2014 to March 2016 were selected, and they were diagnosed by head computed tomography (CT) and magnetic resonance imaging (MRI) and received routine laboratory tests (such as erythrocyte sedimentation rate, white blood cell count, urine detection), which are in line with the relevant diagnostic criteria formulated in the Fourth National Cerebrovascular Disease Conference. Under the condition that patients or their family members signed the informed consent, patients were randomly divided into the control group (n=30) and the experimental group (n=30). In the control group, there were 14 males and 16 females with the average age of 54.9&#x000b1;5.4 years. In the experimental group, there were 18 males and 12 females with the mean age of 52.6&#x000b1;3.9 years. There were no statistically significant differences between the two groups in terms of general data, and the data were comparable. The study was approved by the Ethics Committee of The First People's Hospital of Jining. Written informed consents were signed by the patients and/or guardians.</p><p>Experimental grouping. Patients in the control group received routine anti-infection and dehydration treatments to reduce intracranial pressure and symptomatic and supportive treatments were provided, thus preventing complications. Patients in the experimental group were treated with intravenous infusion of GM1 (Sai Dian; National Medicine Permission no. H20093980; 2 ml each one; Beijing Science Sun Pharmaceutical Co., Ltd., Beijing, China) with 2 ml each time and once a day for 14 days on the basis of routine treatments.</p><p>Observational indexes</p></sec><sec><title>Detection of biochemical indexes</title><p>Ten milliliters whole blood of each patient was taken intravenously before and after treatment. The blood was coagulated at room temperature for 1 h. After centrifugation, the serum was stored at 80&#x000b0;C, and the statistical monitoring was conducted for all samples after collection.</p><p>Serum tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) was measured by horseradish peroxidase-labeled sandwich immunoassay. In short, antibodies against TNF-&#x003b1; (75 kDa) were coated in each well of a 96-well plate and incubated after the addition of an appropriate amount of serum. The content of enzyme and enzyme-bound TNF-&#x003b1; was determined using tetramethyl-benzidine as the substrate. The optical density (OD) values at the dual wavelengths of 450 and 600 nm were measured under the microplate reader, and the sample concentration was calculated.</p><p>The experimental methods of Gao <italic>et al</italic> were used for reference (<xref rid="b9-etm-0-0-5995" ref-type="bibr">9</xref>). The content of superoxide dismutase (SOD) was determined by xanthine oxidase assay, and the content of malondialdehyde (MDA) was detected by the thiobarbituric acid method.</p></sec><sec><title>Observations of haemodynamics</title><p>The Medesonic Transpect thermal conductivity detector (TCD) produced in the US was applied. Two megahertz pulsed Doppler ultrasonography was used to detect peak velocity (Vp) and mean velocity (Vm) from the temporal window at the depth of 50&#x02013;65 mm, and the symmetry [peak velocity difference (DVp) and mean velocity difference (DVm)] of both sides were observed.</p></sec><sec><title>Evaluation of clinical curative effects</title><p>Study methods of Daousi <italic>et al</italic> were used for reference for neurological deficit score (NDS) (<xref rid="b10-etm-0-0-5995" ref-type="bibr">10</xref>). The evaluation criteria for the curative effect are based on the relevant criteria formulated in the Fourth National Cerebrovascular Disease Conference (<xref rid="b11-etm-0-0-5995" ref-type="bibr">11</xref>), and judgments were made combined with clinical symptoms and signs of patients. Total effective rate = obviously effective rate + effective rate.</p><p>Statistical methods. The results were analyzed using GraphPad Prism software Version 5.01 (GraphPad Software, San Diego, Chile). Measurement data are expressed as mean &#x000b1; SD, and differences between indexes were detected using the paired t-test. Count data were detected by the &#x003c7;<sup>2</sup> test. Pearson's correlation coefficient was used to analyze the correlation between TNF-&#x003b1; and NDS. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Detection of the expression level of serum TNF-&#x003b1; by the enzyme-linked immunosorbent assay (ELISA)</title><p>As shown in <xref rid="f1-etm-0-0-5995" ref-type="fig">Fig. 1</xref>, the serum TNF-&#x003b1; content in the experimental group was 25.89&#x000b1;9.157 ng/l after two weeks of GM1 treatment, while the serum TNF-&#x003b1; content in the control group was 55.83&#x000b1;11.71 ng/l, which was significantly higher than that in the experimental group (P&#x0003c;0.05).</p></sec><sec><title>NDS</title><p>As shown in <xref rid="tI-etm-0-0-5995" ref-type="table">Table I</xref>, the difference in the NDS between the experimental group and the control group was not statistically significant before the experiment (P&#x0003e;0.05). The NDS was 25.54&#x000b1;5.83 in the control group and 16.34&#x000b1;8.41 in the experimental group after treatment, which was significantly lower than that in the control group (P&#x0003c;0.05).</p><p>Correlation between the expression level of TNF-&#x003b1; and NDS. Pearsons correlation coefficient (<xref rid="f2-etm-0-0-5995" ref-type="fig">Fig. 2</xref>) showed that the content of TNF-&#x003b1; in the patients was positively correlated with the NDS (r=4.321, P&#x0003c;0.05).</p></sec><sec><title>Contents of serum MDA and SOD in two groups of patients</title><p>As shown in <xref rid="tII-etm-0-0-5995" ref-type="table">Table II</xref>, the contents of serum MDA and SOD in two groups of patients were not statistically different before the experiment (P&#x0003e;0.05). The content of serum MDA of patient in the experimental group was lower than that in the control group, while the content of SOD was significantly higher than that in the control group after treatment (P&#x0003c;0.05).</p></sec><sec><title>Changes in hemodynamic parameters before and after GM1 treatment</title><p>After GM1 treatment, the Vp and Vm in the blood of patients in the experimental group were significantly increased compared with those in the control group (P&#x0003c;0.05), while the DVp and DVm in the experimental group were significantly decreased compared with those in the control group (P&#x0003c;0.05) (<xref rid="tIII-etm-0-0-5995" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparison of the clinical recovery time between two groups of patients</title><p>Main clinical manifestations of patients with severe ischemic brain injury are disturbance of consciousness and abnormalities in muscle tension and original reflexes and with the alleviation of the disease, these symptoms will also improve. Results of this study (<xref rid="tIV-etm-0-0-5995" ref-type="table">Table IV</xref>) revealed that the reflex recovery time, muscle tension recovery time and consciousness recovery time in the experimental group were significantly shorter than those in the control group (P&#x0003c;0.05), and the differences were statistically significant (P&#x0003c;0.05).</p></sec><sec><title>Comparison of the clinical curative effect between two groups of patients</title><p>After 2 months of treatment, the total effective rate of patients in the control group was 66.67% and that of patients in the experimental group was 87.18%. The results (<xref rid="tV-etm-0-0-5995" ref-type="table">Table V</xref>) showed that the clinical curative effect of the experimental group was better than that of the control group (P&#x0003c;0.05).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>A pathological study has shown that ischemic injury can lead to different types of neuronal cell primary and necrotic cell death (<xref rid="b11-etm-0-0-5995" ref-type="bibr">11</xref>). The hippocampal CA1 pyramidal neuron is found to be the most vulnerable and most common injury, which is often the leading cause of memory impairment in patients (<xref rid="b12-etm-0-0-5995" ref-type="bibr">12</xref>,<xref rid="b13-etm-0-0-5995" ref-type="bibr">13</xref>), and the cerebellar Purkinje cell injury leads to torso ataxia of patients (<xref rid="b14-etm-0-0-5995" ref-type="bibr">14</xref>). With the prolongation of ischemic time, the pyramidal cell layer, mitral neurons and striatum neurons of the thalamus are damaged to varying degrees (<xref rid="b15-etm-0-0-5995" ref-type="bibr">15</xref>,<xref rid="b16-etm-0-0-5995" ref-type="bibr">16</xref>). In this study, the NDS of patients was significantly decreased after GM1 treatment, and the reflex recovery time, muscle tension recovery time and consciousness recovery time were significantly shorter than those in the control group, which suggested that GM1 significantly protects the nervous system of patients with severe cerebral ischemic injury.</p><p>Under normal physiological conditions, oxygen free radicals (oxygen free radicals, H<sub>2</sub>O<sub>2</sub> and OH) in the cells are produced in the cytoplasm and mitochondria, and then are rapidly removed under the action of endogenous anti-oxidants (SOD) (<xref rid="b17-etm-0-0-5995" ref-type="bibr">17</xref>). During the hypoxia-ischemia, the amount of generated oxygen free radicals is more than the nervous system can protect, so they cause brain injuries by attacking polyunsaturated fats. If oxygen free radicals cannot be removed in time, they will cause lipid peroxidation, thus leading to the formation of lipid peroxides (MDA) so as to further damage brain tissues (<xref rid="b18-etm-0-0-5995" ref-type="bibr">18</xref>). In the present study, it was found that GM1 significantly increased the level of SOD in patients while reducing MDA content, indicating that GM1 can restore the balance of oxygen free radical reaction and lipid peroxidation in patients.</p><p>Inflammatory mediators play a key role in the pathogenesis of severe ischemic brain injury (<xref rid="b19-etm-0-0-5995" ref-type="bibr">19</xref>,<xref rid="b20-etm-0-0-5995" ref-type="bibr">20</xref>). TNF-&#x003b1; is a proinflammatory cytokine. In previous studies, TNF-&#x003b1; messenger ribonucleic acid (mRNA) has been confirmed to be expressed in the brain at 1&#x02013;4 h after hypoxia-ischemia. TNF-&#x003b1; at high concentration causes neuronal apoptosis by mediating the caspase-8 pathway, but reducing TNF-&#x003b1; receptors can decrease neuronal injuries (<xref rid="b21-etm-0-0-5995" ref-type="bibr">21</xref>,<xref rid="b22-etm-0-0-5995" ref-type="bibr">22</xref>). The inhibition of TNF-&#x003b1; is beneficial in maintaining neurological function and protecting nerve cells from neurotoxicity. Consistent with these findings, the results of this study showed that the level of serum TNF-&#x003b1; in the experimental group was significantly decreased compared with that in the control group and was positively correlated with the NDS, suggesting that GM1 inhibits the expression of TNF-&#x003b1; and alleviates the neurological function of ischemic brain injury, and TNF-&#x003b1; is also a clinical index to evaluate the neurological function of patients with ischemic brain injury.</p><p>In conclusion, this study revealed that good clinical benefits were achieved using GM1 in the treatment of severe ischemic brain injury. Other studies have shown that GM1 inhibits TNF-&#x003b1; level in patients, reduces systematic NDS, improves patient blood flow, regulates the balance of oxygen free radical responses and lipid peroxidation in patients and significantly shortens the clinical recovery time of patients.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><sec><title>Funding</title><p>No funding was received.</p></sec><sec><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.</p></sec><sec><title>Authors' contributions</title><p>FL and YiZ designed, conducted the study and analyzed the data. FL and YiZ wrote the manuscript. FL and YuZ collected and analyzed the fundemental data of patients. XS interpreted the biochemical indexes, haemodynamics and evaluation of clinical curative effects. GZ conducted the measurements of serum TNF-&#x003b1; and YL evaluated the neurological defcit score (NDS). All authors read and approved the final manuscript.</p></sec><sec><title>Ethics approval and consent to participate</title><p>The study was approved by the Ethics Committee of The First People's Hospital of Jining (Jining). Written informed consents were signed by the patients and/or guardians.</p></sec><sec><title>Consent for publication</title><p>Not applicable.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><ref-list><title>References</title><ref id="b1-etm-0-0-5995"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>BRS</given-names></name><name><surname>Reutens</surname><given-names>DC</given-names></name><name><surname>Sobey</surname><given-names>CG</given-names></name></person-group><article-title>Apoptotic mechanisms after cerebral ischemia</article-title><source>Stroke</source><volume>40</volume><fpage>e331</fpage><lpage>e339</lpage><year>2009</year><pub-id pub-id-type="doi">10.1161/STROKEAHA.108.531632</pub-id><pub-id pub-id-type="pmid">19182083</pub-id></element-citation></ref><ref id="b2-etm-0-0-5995"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlert</surname><given-names>P</given-names></name><name><surname>Knipp</surname><given-names>SC</given-names></name><name><surname>Schlamann</surname><given-names>M</given-names></name><name><surname>Thielmann</surname><given-names>M</given-names></name><name><surname>Al-Rashid</surname><given-names>F</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>U</given-names></name><name><surname>Wendt</surname><given-names>D</given-names></name><name><surname>Jakob</surname><given-names>HG</given-names></name><name><surname>Forsting</surname><given-names>M</given-names></name><etal/></person-group><article-title>Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: A diffusion-weighted magnetic resonance imaging study</article-title><source>Circulation</source><volume>121</volume><fpage>870</fpage><lpage>878</lpage><year>2010</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.855866</pub-id><pub-id pub-id-type="pmid">20177005</pub-id></element-citation></ref><ref id="b3-etm-0-0-5995"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>H</given-names></name><name><surname>Plate</surname><given-names>KH</given-names></name></person-group><article-title>Angiogenesis after cerebral ischemia</article-title><source>Acta Neuropathol</source><volume>117</volume><fpage>481</fpage><lpage>496</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s00401-009-0483-6</pub-id><pub-id pub-id-type="pmid">19142647</pub-id></element-citation></ref><ref id="b4-etm-0-0-5995"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossmann</surname><given-names>KA</given-names></name></person-group><article-title>Treatment of experimental cerebral ischemia</article-title><source>J Cereb Blood Flow Metab</source><volume>2</volume><fpage>275</fpage><lpage>297</lpage><year>1982</year><pub-id pub-id-type="doi">10.1038/jcbfm.1982.30</pub-id><pub-id pub-id-type="pmid">7096456</pub-id></element-citation></ref><ref id="b5-etm-0-0-5995"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Hachinski</surname><given-names>V</given-names></name></person-group><article-title>Hypothermia as a potential treatment for cerebral ischemia</article-title><source>Cerebrovasc Brain Metab Rev</source><volume>5</volume><fpage>277</fpage><lpage>300</lpage><year>1993</year><pub-id pub-id-type="pmid">8110595</pub-id></element-citation></ref><ref id="b6-etm-0-0-5995"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>MD</given-names></name></person-group><article-title>Current status of neuroprotection for cerebral ischemia: Synoptic overview</article-title><source>Stroke</source><volume>40</volume><issue>Suppl 3</issue><fpage>S111</fpage><lpage>S114</lpage><year>2009</year><pub-id pub-id-type="doi">10.1161/STROKEAHA.108.528877</pub-id><pub-id pub-id-type="pmid">19064810</pub-id></element-citation></ref><ref id="b7-etm-0-0-5995"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledeen</surname><given-names>RW</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name></person-group><article-title>The multi-tasked life of GM1 ganglioside, a true factotum of nature</article-title><source>Trends Biochem Sci</source><volume>40</volume><fpage>407</fpage><lpage>418</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.tibs.2015.04.005</pub-id><pub-id pub-id-type="pmid">26024958</pub-id></element-citation></ref><ref id="b8-etm-0-0-5995"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>YH</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>ZP</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>N</given-names></name></person-group><article-title>Effects of ganglioside GM1 and neural growth factor on neural stem cell proliferation and differentiation</article-title><source>Genet Mol Res</source><month>8</month><day>5</day><year>2016</year><comment>(Epub ahead of print). doi: 10.4238/gmr.15038376</comment></element-citation></ref><ref id="b9-etm-0-0-5995"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment</article-title><source>Urology</source><volume>79</volume><fpage>391</fpage><lpage>396</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.urology.2011.08.046</pub-id><pub-id pub-id-type="pmid">22100490</pub-id></element-citation></ref><ref id="b10-etm-0-0-5995"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daousi</surname><given-names>C</given-names></name><name><surname>Benbow</surname><given-names>SJ</given-names></name><name><surname>Woodward</surname><given-names>A</given-names></name><name><surname>MacFarlane</surname><given-names>IA</given-names></name></person-group><article-title>The natural history of chronic painful peripheral neuropathy in a community diabetes population</article-title><source>Diabet Med</source><volume>23</volume><fpage>1021</fpage><lpage>1024</lpage><year>2006</year><pub-id pub-id-type="doi">10.1111/j.1464-5491.2006.01904.x</pub-id><pub-id pub-id-type="pmid">16922710</pub-id></element-citation></ref><ref id="b11-etm-0-0-5995"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Summary of the Fourth National Cerebrovascular Disease Conference</article-title><source>Stroke Nerv Dis:</source><volume>4</volume><fpage>105</fpage><lpage>109</lpage><year>1997</year></element-citation></ref><ref id="b12-etm-0-0-5995"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niizuma</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>GS</given-names></name><name><surname>Jung</surname><given-names>JE</given-names></name><name><surname>Katsu</surname><given-names>M</given-names></name><name><surname>Okami</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>PH</given-names></name></person-group><article-title>Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia</article-title><source>Mol Basis Dis</source><volume>1802</volume><fpage>92</fpage><lpage>99</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.bbadis.2009.09.002</pub-id></element-citation></ref><ref id="b13-etm-0-0-5995"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Chu</surname><given-names>KT</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>LN</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>BY</given-names></name></person-group><article-title>Severe global cerebral ischemia-induced programmed necrosis of hippocampal CA1 neurons in rat is prevented by 3-methyladenine: A widely used inhibitor of autophagy</article-title><source>J Neuropathol Exp Neurol</source><volume>70</volume><fpage>314</fpage><lpage>322</lpage><year>2011</year><pub-id pub-id-type="doi">10.1097/NEN.0b013e31821352bd</pub-id><pub-id pub-id-type="pmid">21412169</pub-id></element-citation></ref><ref id="b14-etm-0-0-5995"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Leptin protects hippocampal CA1 neurons against ischemic injury</article-title><source>J Neurochem</source><volume>107</volume><fpage>578</fpage><lpage>587</lpage><year>2008</year><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05645.x</pub-id><pub-id pub-id-type="pmid">18752642</pub-id></element-citation></ref><ref id="b15-etm-0-0-5995"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name></person-group><article-title>Postconditioning with isoflurane reduced ischemia-induced brain injury in rats</article-title><source>Anesthesiology</source><volume>108</volume><fpage>1055</fpage><lpage>1062</lpage><year>2008</year><pub-id pub-id-type="doi">10.1097/ALN.0b013e3181730257</pub-id><pub-id pub-id-type="pmid">18497606</pub-id></element-citation></ref><ref id="b16-etm-0-0-5995"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Zoppo</surname><given-names>GJ</given-names></name><name><surname>Zoppo</surname><given-names>G</given-names></name></person-group><article-title>Inflammation and the neurovascular unit in the setting of focal cerebral ischemia</article-title><source>Neuroscience</source><volume>158</volume><fpage>972</fpage><lpage>982</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.08.028</pub-id><pub-id pub-id-type="pmid">18824084</pub-id></element-citation></ref><ref id="b17-etm-0-0-5995"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>JL</given-names></name><name><surname>Lu</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>SP</given-names></name></person-group><article-title>Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats</article-title><source>Neurobiol Dis</source><volume>46</volume><fpage>635</fpage><lpage>645</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.nbd.2012.03.002</pub-id><pub-id pub-id-type="pmid">22426403</pub-id></element-citation></ref><ref id="b18-etm-0-0-5995"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niatsetskaya</surname><given-names>ZV</given-names></name><name><surname>Sosunov</surname><given-names>SA</given-names></name><name><surname>Matsiukevich</surname><given-names>D</given-names></name><name><surname>Utkina-Sosunova</surname><given-names>IV</given-names></name><name><surname>Ratner</surname><given-names>VI</given-names></name><name><surname>Starkov</surname><given-names>AA</given-names></name><name><surname>Ten</surname><given-names>VS</given-names></name></person-group><article-title>The oxygen free radicals originating from mitochondrial complex I contribute to oxidative brain injury following hypoxia-ischemia in neonatal mice</article-title><source>J Neurosci</source><volume>32</volume><fpage>3235</fpage><lpage>3244</lpage><year>2012</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6303-11.2012</pub-id><pub-id pub-id-type="pmid">22378894</pub-id></element-citation></ref><ref id="b19-etm-0-0-5995"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Mittal</surname><given-names>R</given-names></name><name><surname>Khanna</surname><given-names>HD</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name></person-group><article-title>Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy</article-title><source>Pediatrics</source><volume>122</volume><fpage>e722</fpage><lpage>e727</lpage><year>2008</year><pub-id pub-id-type="doi">10.1542/peds.2008-0269</pub-id><pub-id pub-id-type="pmid">18725389</pub-id></element-citation></ref><ref id="b20-etm-0-0-5995"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candelario-Jalil</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia</article-title><source>Neuroscience</source><volume>158</volume><fpage>983</fpage><lpage>994</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.06.025</pub-id><pub-id pub-id-type="pmid">18621108</pub-id></element-citation></ref><ref id="b21-etm-0-0-5995"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Alexander</surname><given-names>M</given-names></name></person-group><article-title>Cerebral ischemia and inflammation</article-title><source>Curr Opin Neurol</source><volume>14</volume><fpage>89</fpage><lpage>94</lpage><year>2001</year><pub-id pub-id-type="doi">10.1097/00019052-200102000-00014</pub-id><pub-id pub-id-type="pmid">11176223</pub-id></element-citation></ref><ref id="b22-etm-0-0-5995"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;nther</surname><given-names>C</given-names></name><name><surname>Buchen</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>GW</given-names></name><name><surname>Hornef</surname><given-names>M</given-names></name><name><surname>Torow</surname><given-names>N</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Wittkopf</surname><given-names>N</given-names></name><name><surname>Martini</surname><given-names>E</given-names></name><name><surname>Basic</surname><given-names>M</given-names></name><name><surname>Bleich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Caspase-8 controls the gut response to microbial challenges by TNF-&#x003b1;-dependent and independent pathways</article-title><source>Gut</source><volume>64</volume><fpage>601</fpage><lpage>610</lpage><year>2015</year><pub-id pub-id-type="doi">10.1136/gutjnl-2014-307226</pub-id><pub-id pub-id-type="pmid">25379949</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-0-0-5995" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Detection of the contents of serum tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) in two groups of patients by enzyme-linked immunosorbent assay (ELISA). **Compared with control group, P&#x0003c;0.05.</p></caption><graphic xlink:href="etm-15-06-4851-g00"/></fig><fig id="f2-etm-0-0-5995" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Correlation between the expression level of serum tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and the NDS in two groups of patients. NDS, neuropathy disability score.</p></caption><graphic xlink:href="etm-15-06-4851-g01"/></fig><table-wrap id="tI-etm-0-0-5995" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of the NDS between two groups of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before experiment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After experiment</th><th align="center" valign="bottom" rowspan="1" colspan="1">t-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">33.12&#x000b1;2.37</td><td align="center" valign="top" rowspan="1" colspan="1">25.54&#x000b1;5.83<sup><xref rid="tfn1-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">1.270</td><td align="center" valign="top" rowspan="1" colspan="1">0.0431</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">32.58&#x000b1;1.95</td><td align="center" valign="top" rowspan="1" colspan="1">16.34&#x000b1;8.41<sup><xref rid="tfn1-etm-0-0-5995" ref-type="table-fn">a</xref>,<xref rid="tfn2-etm-0-0-5995" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">2.032</td><td align="center" valign="top" rowspan="1" colspan="1">0.0092</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.652</td><td align="center" valign="top" rowspan="1" colspan="1">1.745</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.347</td><td align="center" valign="top" rowspan="1" colspan="1">0.0282</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-5995"><label>a</label><p>P&#x0003e;0.05 compared with that before experiment</p></fn><fn id="tfn2-etm-0-0-5995"><label>b</label><p>P&#x0003e;0.01 compared with that in the control group. NDS, neuropathy disability score.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-5995" orientation="portrait" position="float"><label>Table II.</label><caption><p>Detection of contents of serum MDA and SOD in two groups of patients (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Detection time</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">MDA (nmol/100 mg)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SOD (nmol/100 mg)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Before experiment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">87.18&#x000b1;5.92</td><td align="center" valign="top" rowspan="1" colspan="1">184.25&#x000b1;10.04</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">90.51&#x000b1;7.33</td><td align="center" valign="top" rowspan="1" colspan="1">178.23&#x000b1;8.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">After experiment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">72.34&#x000b1;6.45<sup><xref rid="tfn3-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">158.73&#x000b1;12.57<sup><xref rid="tfn4-etm-0-0-5995" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">50.81&#x000b1;10.88<sup><xref rid="tfn5-etm-0-0-5995" ref-type="table-fn">c</xref>,<xref rid="tfn6-etm-0-0-5995" ref-type="table-fn">d</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">120.75&#x000b1;6.82<sup><xref rid="tfn5-etm-0-0-5995" ref-type="table-fn">c</xref>,<xref rid="tfn6-etm-0-0-5995" ref-type="table-fn">d</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-0-0-5995"><label>a</label><p>P&#x0003c;0.05</p></fn><fn id="tfn4-etm-0-0-5995"><label>b</label><p>P&#x0003c;0.01</p></fn><fn id="tfn5-etm-0-0-5995"><label>c</label><p>P&#x0003c;0.001 compared with those before experiment</p></fn><fn id="tfn6-etm-0-0-5995"><label>d</label><p>P&#x0003c;0.01 compared with those in the control group. MDA, malondialdehyde; SOD, superoxide dismutase; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-5995" orientation="portrait" position="float"><label>Table III.</label><caption><p>Detection of changes in hemodynamic parameters of two groups of patients before and after GM1 treatment (mean &#x000b1; SD, mm/sec).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Detection time</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vp</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vm</th><th align="center" valign="bottom" rowspan="1" colspan="1">DVp</th><th align="center" valign="bottom" rowspan="1" colspan="1">DVm</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Before experiment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">47.36&#x000b1;5.62</td><td align="center" valign="top" rowspan="1" colspan="1">32.17&#x000b1;3.57</td><td align="center" valign="top" rowspan="1" colspan="1">26.05&#x000b1;3.89</td><td align="center" valign="top" rowspan="1" colspan="1">15.04&#x000b1;2.16</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">48.92&#x000b1;4.77</td><td align="center" valign="top" rowspan="1" colspan="1">33.23&#x000b1;3.61</td><td align="center" valign="top" rowspan="1" colspan="1">25.58&#x000b1;2.80</td><td align="center" valign="top" rowspan="1" colspan="1">14.43&#x000b1;2.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">After experiment</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">67.23&#x000b1;11.40<sup><xref rid="tfn8-etm-0-0-5995" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">38.76&#x000b1;4.03<sup><xref rid="tfn7-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">15.63&#x000b1;3.52<sup><xref rid="tfn7-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">7.32&#x000b1;1.42<sup><xref rid="tfn7-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">85.04&#x000b1;8.68<sup><xref rid="tfn9-etm-0-0-5995" ref-type="table-fn">c</xref>,<xref rid="tfn10-etm-0-0-5995" ref-type="table-fn">d</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">44.37&#x000b1;5.36<sup><xref rid="tfn7-etm-0-0-5995" ref-type="table-fn">a</xref>,<xref rid="tfn11-etm-0-0-5995" ref-type="table-fn">e</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">10.25&#x000b1;4.63<sup><xref rid="tfn8-etm-0-0-5995" ref-type="table-fn">b</xref>,<xref rid="tfn11-etm-0-0-5995" ref-type="table-fn">e</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3.65&#x000b1;0.77<sup><xref rid="tfn8-etm-0-0-5995" ref-type="table-fn">b</xref>,<xref rid="tfn10-etm-0-0-5995" ref-type="table-fn">d</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn7-etm-0-0-5995"><label>a</label><p>P&#x0003c;0.05</p></fn><fn id="tfn8-etm-0-0-5995"><label>b</label><p>P&#x0003c;0.01</p></fn><fn id="tfn9-etm-0-0-5995"><label>c</label><p>P&#x0003c;0.001 compared with those before experiment</p></fn><fn id="tfn10-etm-0-0-5995"><label>d</label><p>P&#x0003c;0.05</p></fn><fn id="tfn11-etm-0-0-5995"><label>e</label><p>P&#x0003c;0.01 compared with those in the control group. GM1, monosialotetrahexosylganglioside; SD, standard deviation; SD, standard deviation; mm/sec, millimeter per seconds.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-5995" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparison of the clinical recovery time between two groups of patients (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reflex recovery time (day)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Muscle tension recovery time (day)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Consciousness recoverytime (day)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">10.34&#x000b1;1.87</td><td align="center" valign="top" rowspan="1" colspan="1">10.50&#x000b1;1.42</td><td align="center" valign="top" rowspan="1" colspan="1">9.47&#x000b1;1.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">6.83&#x000b1;3.26<sup><xref rid="tfn13-etm-0-0-5995" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">8.62&#x000b1;2.73<sup><xref rid="tfn12-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">5.22&#x000b1;1.99<sup><xref rid="tfn12-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.34</td><td align="center" valign="top" rowspan="1" colspan="1">1.85</td><td align="center" valign="top" rowspan="1" colspan="1">4.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.028</td><td align="center" valign="top" rowspan="1" colspan="1">0.041</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr></tbody></table><table-wrap-foot><fn id="tfn12-etm-0-0-5995"><label>a</label><p>P&#x0003c;0.01</p></fn><fn id="tfn13-etm-0-0-5995"><label>b</label><p>P&#x0003c;0.01 compared with those in the control group. SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tV-etm-0-0-5995" orientation="portrait" position="float"><label>Table V.</label><caption><p>Comparison of the clinical curative effect between two groups of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Obviously effective</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ineffective</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total effective rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">63.33%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Experimental</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">93.33%<sup><xref rid="tfn14-etm-0-0-5995" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.017</td></tr></tbody></table><table-wrap-foot><fn id="tfn14-etm-0-0-5995"><label>a</label><p>P&#x0003c;0.05 compared with those in the control group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>